Role of Dapagliflozin (a drug given to treat diabetes) in maintaining sodium levels in the body in patients having kidney disease and its role in preventing heart related problem.
Not Applicable
- Conditions
- Health Condition 1: N189- Chronic kidney disease, unspecified
- Registration Number
- CTRI/2023/09/057731
- Lead Sponsor
- I
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients, age of 18 years and above who present with Chronic kidney disease with complication.
Patients who receive Dapagliflozin (Test cohort) and who do not receive Dapagliflozin (Reference cohort)
Exclusion Criteria
Pregnant and paediatric patients. Patients with any other complications apart from diabetes, hypertension or cardiovascular complications present along with chronic kidney disease.
Patients in End stage renal disease and are receiving dialysis.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the level of sodium & glucose in patients with chronic kidney disease who are receiving Dapagliflozin.Timepoint: Follow up will be done after one month wherein the data will be collected from the tests suggested by the physician
- Secondary Outcome Measures
Name Time Method To determine the incidence or frequency of cardiovascular occurring in patients with chronic kidney disease receiving DapagliflozinTimepoint: Follow up will be done after one month wherein the data will be collected from the tests suggested by the physician